Objectives: To test whether age, sex, body mass index (BMI), and the apolipoprotein E (APOE) genotype are associated with the metabolic response to an n-3 polyunsaturated fatty acid (PUFA) supplementation. Methods: 210 subjects followed a 2-week run-in period based on Canada's Food Guide and underwent a 6-week 5 g/day fish oil supplementation (1.9 g of eicosapentaenoic acid and 1.1 g of docosahexaenoic acid). Cardiovascular disease risk factors were measured. Results: n-3 PUFA supplementation was associated with a decrease of plasma triglyceride levels (p = 0.0002) as well as with an increase of fasting glucose (FG) levels (p = 0.02). Age was associated with post-intervention plasma total cholesterol (p = 0.01), low-density lipoprotein cholesterol (p = 0.007), apolipoprotein B (p = 0.04), and insulin (p = 0.002) levels. Sex was associated with post-intervention plasma high-density lipoprotein cholesterol levels (p = 0.02). BMI was associated with plasma FG (p = 0.02) and insulin levels (p < 0.0001) after the supplementation. APOE genotype was associated with FG (p = 0.001) and C-reactive protein levels (p = 0.03) after the supplementation. Conclusion: Results suggest that age, sex, BMI, and the APOE genotype contribute to the inter-individual variability observed in the metabolic response to an n-3 PUFA supplementation.

Keywords:
n-3 polyunsaturated fatty acids, Plasma lipids, Cardiovascular disease risk factors
1.
Tracking Heart Disease and Stroke in Canada, 2009. http://www.phac-aspc.gc.ca/publicat/2009/cvd-avc/pdf/cvd-avs-2009-eng.pdf (accessed April 15, 2013).
2.
Gupta R, Misra A, Vikram NK, Kondal D, Gupta SS, Agrawal A, Pandey RM: Younger age of escalation of cardiovascular risk factors in Asian Indian subjects. BMC Cardiovasc Disord 2009;9:28.
3.
Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-2757.
4.
Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-761.
5.
Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003;23:e20-e30.
6.
Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV, Durrington PN, Higgins JP, Capps NE, et al: Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006;332:752-760.
7.
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, et al: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-1098.
8.
Silverberg DS, Schwartz D: The role of iron, omega-3 fatty acids, and vitamins in heart failure. Curr Treat Options Cardiovasc Med 2012;14:328-341.
9.
Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J: Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006;189:19-30.
10.
Chin JP, Gust AP, Nestel PJ, Dart AM: Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 1993;21:22-28.
11.
Harris WS: n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65(5 suppl):1645S-1654S.
12.
Mori TA: Omega-3 fatty acids and hypertension in humans. Clin Exp Pharmacol Physiol 2006;33:842-846.
13.
Defilippis AP, Blaha MJ, Jacobson TA: Omega-3 fatty acids for cardiovascular disease prevention. Curr Treat Options Cardiovasc Med 2010;12:365-380.
14.
Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE: Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 1998;21:494-500.
15.
Montori VM, Farmer A, Wollan PC, Dinneen SF: Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000;23:1407-1415.
16.
Johnson JL, Slentz CA, Duscha BD, Samsa GP, McCartney JS, Houmard JA, Kraus WE: Gender and racial differences in lipoprotein subclass distributions: the STRRIDE study. Atherosclerosis 2004;176:371-377.
17.
Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, Grundy SM, Johnson CL: Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005;294:1773-1781.
18.
McNamara RK, Able J, Jandacek R, Rider T, Tso P: Gender differences in rat erythrocyte and brain docosahexaenoic acid composition: role of ovarian hormones and dietary omega-3 fatty acid composition. Psychoneuroendocrinology 2009;34:532-539.
19.
Decsi T, Kennedy K: Sex-specific differences in essential fatty acid metabolism. Am J Clin Nutr 2011;94(6 suppl):1914S-1919S.
20.
Mueller BA, Talbert BL, Tegeler CH: Comparative effects of omega-3 fatty acids in men and women. Clin Pharm 1989;8:328-329.
21.
Caslake MJ, Miles EA, Kofler BM, Lietz G, Curtis P, Armah CK, Kimber AC, Grew JP, Farrell L, Stannard J, et al: Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. Am J Clin Nutr 2008;88:618-629.
22.
Huebbe P, Schaffer S, Jofre-Monseny L, Boesch-Saadatmandi C, Minihane AM, Muller WE, Eckert GP, Rimbach G: Apolipoprotein E genotype and alpha-tocopherol modulate amyloid precursor protein metabolism and cell cycle regulation. Mol Nutr Food Res 2007;51:1510-1517.
23.
Sarkkinen E, Korhonen M, Erkkila A, Ebeling T, Uusitupa M: Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. Am J Clin Nutr 1998;68:1215-1222.
24.
Minihane AM, Khan S, Leigh-Firbank EC, Talmud P, Wright JW, Murphy MC, Griffin BA, Williams CM: ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2000;20:1990-1997.
25.
Goulet J, Nadeau G, Lapointe A, Lamarche B, Lemieux S: Validity and reproducibility of an interviewer-administered food frequency questionnaire for healthy French-Canadian men and women. Nutr J 2004;3:13.
26.
Callaway CW: CWBC Standardization of Anthropometric Measurements. The Airlie (VA) Consensus Conference. Champaign, IL, Human Kinetics Publishers, 1988.
27.
McNamara JR, Schaefer EJ: Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987;166:1-8.
28.
Burstein M, Samaille J: On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins. Clin Chim Acta 1960;5:609.
29.
Warnick GR, Albers JJ, Bachorik PS, Turner JD, Garcia C, Breckinridge C, Kuba K, McNeely S, Hillerman G, King P, et al: Multilaboratory evaluation of an ultrafiltration procedure for high density lipoprotein cholesterol quantification in turbid heparin-manganese supernates. J Lipid Res 1981;22:1015-1020.
30.
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
31.
Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Despres JP, Lamarche B: Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 2001;161:2474-2480.
32.
Laurell CB: Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966;15:45-52.
33.
Desbuquois B, Aurbach GD: Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 1971;33:732-738.
34.
Richterich R, Dauwalder H: Determination of plasma glucose by hexokinase-glucose-6-phosphate dehydrogenase method. Schweiz Med Wochenschr 1971;101:615-618.
35.
Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
36.
Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, et al: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-2333.
37.
WHO: Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation. WHO, 2000.
38.
Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC: Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155:487-495.
39.
Robitaille N, Cormier G, Couture R, Bouthillier D, Davignon J, Perusse L: Apolipoprotein E polymorphism in a French Canadian population of northeastern Quebec: allele frequencies and effects on blood lipid and lipoprotein levels. Hum Biol 1996;68:357-370.
40.
Skulas-Ray AC, Kris-Etherton PM, Harris WS, Vanden Heuvel JP, Wagner PR, West SG: Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011;93:243-252.
41.
Olano-Martin E, Anil E, Caslake MJ, Packard CJ, Bedford D, Stewart G, Peiris D, Williams CM, Minihane AM: Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis 2010;209:104-110.
42.
Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ: Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002;76:1007-1015.
43.
Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ: Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000;71:1085-1094.
44.
Kabir M, Skurnik G, Naour N, Pechtner V, Meugnier E, Rome S, Quignard-Boulange A, Vidal H, Slama G, Clement K, et al: Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 2007;86:1670-1679.
45.
Griffin MD, Sanders TA, Davies IG, Morgan LM, Millward DJ, Lewis F, Slaughter S, Cooper JA, Miller GJ, Griffin BA: Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 years: the OPTILIP Study. Am J Clin Nutr 2006;84:1290-1298.
46.
Fink RI, Kolterman OG, Griffin J, Olefsky JM: Mechanisms of insulin resistance in aging. J Clin Invest 1983;71:1523-1535.
47.
Karlstrom BE, Jarvi AE, Byberg L, Berglund LG, Vessby BO: Fatty fish in the diet of patients with type 2 diabetes: comparison of the metabolic effects of foods rich in n-3 and n-6 fatty acids. Am J Clin Nutr 2011;94:26-33.
48.
Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U: Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes 1996;45:947-953.
49.
Guarner-Lans V, Rubio-Ruiz ME, Perez-Torres I, Banos de MacCarthy G: Relation of aging and sex hormones to metabolic syndrome and cardiovascular disease. Exp Gerontol 2011;46:517-523.
50.
Kofler BM, Miles EA, Curtis P, Armah CK, Tricon S, Grew J, Napper FL, Farrell L, Lietz G, Packard CJ, et al: Apolipoprotein E genotype and the cardiovascular disease risk phenotype: impact of sex and adiposity (the FINGEN study). Atherosclerosis 2012;221:467-470.
51.
Yoon M, Jeong S, Nicol CJ, Lee H, Han M, Kim JJ, Seo YJ, Ryu C, Oh GT: Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Exp Mol Med 2002;34:481-488.
52.
Trottier J, Caron P, Straka RJ, Barbier O: Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrate. Clin Pharmacol Ther 2011;90:279-286.
53.
Masson LF, McNeill G: The effect of genetic variation on the lipid response to dietary change: recent findings. Curr Opin Lipidol 2005;16:61-67.
54.
Song Y, Stampfer MJ, Liu S: Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004;141:137-147.
55.
Dallongeville J, Lussier-Cacan S, Davignon J: Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992;33:447-454.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.